Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Top Cited Papers
- 1 August 2013
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 369 (5), 438-447
- https://doi.org/10.1056/nejmoa1300439
Abstract
For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk patients who may benefit from early intervention.This publication has 26 references indexed in Scilit:
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized studyLeukemia & Lymphoma, 2011
- Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative ComponentMayo Clinic Proceedings, 2009
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myelomaCancer, 2008
- Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple MyelomaNew England Journal of Medicine, 2007
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003
- Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti‐tumour effectBritish Journal of Haematology, 2002
- Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized studyBritish Journal of Cancer, 2000
- A prognostic index for multiple myelomaBritish Journal of Cancer, 1996
- Initial versus deferred melphalan‐prednisone therapy for asymptomatic multiple myeloma stage I — A randomized studyEuropean Journal of Haematology, 1993